Market Runner: What’s Propelling Benitec Biopharma Ltd (ADR) to Increase So Much?
January 17, 2017 - By Hazel Jackson
The stock of Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) is a huge mover today! About 4.43 million shares traded hands or 22595.83% up from the average. Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) has risen 32.14% since June 10, 2016 and is uptrending. It has outperformed by 23.62% the S&P500.
The move comes after 7 months positive chart setup for the $16.26 million company. It was reported on Jan, 17 by Barchart.com. We have $3.65 PT which if reached, will make NASDAQ:BNTC worth $1.46M more.
According to Zacks Investment Research, “Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.”
More notable recent Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on July 31, 2015, also Seekingalpha.com with their article: “Benitec’s DdRNAi Targeting Fight Against HIV” published on August 13, 2014, Benzinga.com published: “Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates” on January 17, 2017. More interesting news about Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) were released by: Benzinga.com and their article: “Arbutus Biopharma Taken Off Of Chardan’s Sell List” published on June 16, 2016 as well as Benzinga.com‘s news article titled: “10 Biggest Mid-Day Losers For Wednesday” with publication date: January 04, 2017.
BLT Price at posting:
18.0¢ Sentiment: Hold Disclosure: Held
